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AbstrAct
Objective Chronic heart failure with reduced ejection 
fraction (HF-REF) represents a major public health 
issue and is associated with considerable morbidity 
and mortality. We evaluated the cost-effectiveness of 
sacubitril/valsartan (formerly LCZ696) compared with an 
ACE inhibitor (ACEI) (enalapril) in the treatment of HF-
REF from the perspective of healthcare providers in the 
UK, Denmark and Colombia.
Methods A cost-utility analysis was performed based 
on data from a multinational, Phase III randomised 
controlled trial. A decision-analytic model was developed 
based on a series of regression models, which 
extrapolated health-related quality of life, hospitalisation 
rates and survival over a lifetime horizon. The primary 
outcome was the incremental cost-effectiveness ratio 
(ICER).
results In the UK, the cost per quality-adjusted 
life-year (QALY) gained for sacubitril/valsartan (using 
cardiovascular mortality) was £17 100 (€20 400) 
versus enalapril. In Denmark, the ICER for sacubitril/
valsartan was Kr 174 000 (€22 600). In Colombia, the 
ICER was COP$39.5 million (€11 200) per QALY gained. 
Deterministic sensitivity analysis showed that results 
were most sensitive to the extrapolation of mortality, 
duration of treatment effect and time horizon, but were 
robust to other structural changes, with most scenarios 
associated with ICERs below the willingness-to-pay 
threshold for all three country settings. Probabilistic 
sensitivity analysis suggested the probability that 
sacubitril/valsartan was cost-effective at conventional 
willingness-to-pay thresholds was 68%–94% in the UK, 
84% in Denmark and 95% in Colombia.
conclusions Our analysis suggests that, in all three 
countries, sacubitril/valsartan is likely to be cost-effective 
compared with an ACEI (the current standard of care) in 
patients with HF-REF.
IntrOductIOn
Chronic heart failure with reduced ejection frac-
tion (HF-REF) represents a major public health 
issue and is associated with considerable morbidity 
and mortality. Globally, heart failure (HF) affects 
an estimated 26 million people and is responsible 
for 1%–2% of hospitalisations in the USA and 
Europe.1 HF as a primary diagnosis accounts for 
approximately 2% of the UK National Health 
Service (NHS) annual budget,2 and up to 4% of 
healthcare expenditure if hospitalisations with HF 
as a secondary diagnosis and nursing home admis-
sions are considered.2 
The ACE inhibitor (ACEI) enalapril was the first 
treatment shown to reduce the risk of hospitalisation 
and death in patients with HF-REF; ACEIs remain 
the first-line therapeutic option in these patients.3–5 
Despite this and several other therapeutic advances 
in the field, individuals with HF-REF remain at 
high risk of hospitalisation and death and experi-
ence poorer health-related quality of life (HRQL) 
than age-matched and gender-matched individuals 
in the general population.6–8
Sacubitril/valsartan (formerly LCZ696) is a first-
in-class angiotensin receptor neprilysin inhibitor 
(ARNI). The Prospective comparison of ARNI with 
ACEI to Determine Impact on Global Mortality and 
morbidity in Heart Failure (PARADIGM-HF) trial 
was a multinational, Phase III, prospective, 
double-blind, randomised active-controlled trial, 
comparing the effects of sacubitril/valsartan and 
enalapril on mortality and morbidity, in addition to 
standard of care, in patients with chronic HF-REF.9 
PARADIGM-HF demonstrated that, compared with 
enalapril, treatment with sacubitril/valsartan signifi-
cantly reduced the composite primary outcome of 
cardiovascular (CV) death or HF hospitalisation, 
and both components of this composite, by approx-
imately 20%.10
As the drug acquisition cost of sacubitril/valsartan 
is higher than that of an ACEI, reimbursement by 
national payers requires an estimation of expected 
costs and benefits in order to determine value for 
money. This study assesses the cost-effectiveness 
of sacubitril/valsartan versus enalapril from three 
perspectives: the UK, the Danish and the Colom-
bian healthcare systems.
MethOds
Consistent with UK and Danish guidance,1 11 the 
England and Wales National Heart Failure Audit 
(2013) found that 73% of patients discharged with 
HF-REF were treated with ACEI,11 while 18% were 
treated with an angiotensin receptor blocker (ARB). 
Therefore, enalapril was selected as the base case 
comparator in this economic analysis.
A systematic review of economic evaluations of 
chronic HF treatments was performed to inform 
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the design of the economic evaluation. The health states most 
frequently employed were ‘alive’ and ‘dead’, with outcomes such 
as hospitalisation or New York Heart Association (NYHA) func-
tional class distribution considered in the ‘alive’ state. Therefore, 
a decision-analytic model was developed with ‘alive’ and ‘dead’ 
health states to estimate costs and benefits over the population 
lifetime, with hospitalisation rates, HRQL (evaluated using the 
EuroQol-5 Dimension (EQ-5D) index score) and adverse event 
(AE) rates included in the ‘alive’ health states (figure 1).
A 1-month cycle length with half-cycle correction was 
employed. Costs and benefits beyond 1 year were discounted at 
rates of 3.5%, 3% and 5% for the UK, Danish and Colombian 
settings, respectively, according to local guidelines.11–13
The risks of events were estimated, dependent on patients’ 
baseline characteristics (reported previously)10 14 and treatment 
(sacubitril/valsartan or ACEI), through multivariable regression 
models. Outcomes were estimated for each patient in PARA-
DIGM-HF and results presented as the expected costs and 
benefits across the patient cohort. Cost-effectiveness was esti-
mated for all a priori defined subgroups in PARADIGM-HF by 
averaging across the members of the relevant subgroup. The 
primary model outcome was the incremental cost-effectiveness 
ratio (ICER), expressed as the cost per quality-adjusted life-year 
(QALY) gained, reported to the nearest 100 currency units. The 
ICERs for each setting were compared with country-specific 
cost-effectiveness thresholds, as listed in table 1.
Deterministic and probabilistic sensitivity analyses were 
performed to test parameter uncertainty in the model; the 
methods are provided in the online Supplementary file 1.
All statistical analyses were performed using Stata V.13.15 The 
cost-effectiveness model was built in MS Excel.
statistical analysis
Mortality
Multivariable parametric survival analysis (using the full analysis 
set of PARADIGM-HF) was used to model CV mortality over 
time using baseline characteristics and treatment allocation (sacu-
bitril/valsartan or ACEI). The model was applied both during 
and beyond the duration of PARADIGM-HF. The baseline risk 
of CV mortality was assumed to follow a Gompertz distribution, 
selected from potential distributions by clinical experts following 
review of projected life expectancies. Details of model selection 
and the effects of using the Weibull and exponential distributions 
are provided in the  online Supplementary file 1. The base case 
analysis was based on CV mortality from PARADIGM-HF, with 
non-CV mortality estimated using national life tables adjusted to 
remove the risk of CV mortality.16–18
Hospitalisation and AEs
The monthly risk of all-cause hospitalisation was estimated 
using a multivariable negative binomial regression model, 
allowing analysis of count data (in this case, the total number 
of hospitalisations during the double-blind phase of PARA-
DIGM-HF for a patient). Additional details on candidate 
covariates and their selection procedure were the same as 
employed for the model of CV mortality and are provided in 
the online Supplementary file 1.
Figure 1 Conceptual model. QALY, quality-adjusted life-year.
table 1 ICER and cost-effectiveness thresholds in the settings 
considered in the cost-effectiveness model
Icer comparison 
per setting
cost-effectiveness 
threshold/QALY gained source
UK £20 000 (EUR 23 862)* NICE†
£30 000 (EUR 35 793)*
Denmark Kr250 000 (EUR 33 624)‡ National drug reimbursement 
committee
Colombia COP$52.4 million (EUR 
15 975)§
Colombian HTA guidance12
*Exchange rate used: 1 GBP=1.19 EUR.
†National Institute for Health and Care Excellence. Guide to the methods of 
technology appraisal, 2013.
‡Exchange rate used: 1 DKK=0.13 EUR.
§Exchange rate used: COP$1=0.0003 EUR, equivalent to three times Colombian 
GDP.12
COP, Colombian peso; DKK, Danish kroner; EUR, Euro; GBP, British pound 
sterling; GDP, gross domestic product; HTA, health technology assessment; ICER, 
incremental cost-effectiveness ratio; Kr, Danish kroner; QALY, quality-adjusted life-
year.
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AEs used were those reported in the primary analysis of PARA-
DIGM-HF. A constant rate of AEs was assumed over the model 
time horizon.
Health-related quality of life
The EQ-5D tariff published by Dolan19 was applied to EQ-5D 
responses collected in PARADIGM-HF to generate utility values 
for each patient for the UK setting. The tariff published by 
Wittrup-Jensen et al20 was applied to the Danish setting. As there 
is no Colombian EQ-5D tariff, the Dolan tariff was applied in 
the Colombian setting.
A multilevel model of EQ-5D was developed to allow the 
prediction of EQ-5D dependent on baseline characteristics, 
hospitalisation, AEs and time since randomisation. A constant 
decline in EQ-5D common to all patients was assumed as a 
simplifying assumption, and sacubitril/valsartan was assumed to 
confer a constant effect at all time points on HRQL.
The effect of hospitalisation on HRQL was captured through 
the effect on EQ-5D at visits falling 0–30 days and 30–90 days 
post-hospitalisation to capture both acute and medium-term 
effects.
cost-effectiveness model
Model structure
All patients started in the ‘alive’ health state and transitions to 
the ‘dead’ health state were governed by the mortality model. 
During each cycle, the probability of death was calculated based 
on the cohort’s baseline characteristics and the time since rando-
misation. In the ‘alive’ health state, patients were at risk of hospi-
talisations and AEs.
The model structure was constant across the UK, Denmark 
and Colombia, but the data used to inform the model differed 
by country. These differences are summarised in table 2. The 
UK and Colombian models used the PARADIGM-HF patients 
as the base case population in the model, whereas the Danish 
model reweighted the characteristics of the PARADIGM-HF 
patients to more closely match the Danish patient population 
in terms of age, gender, ejection fraction and NYHA class. A 
scenario analysis in which the characteristics of the PARA-
DIGM-HF patients were reweighted to match the UK HF-REF 
population was also performed (see online Supplementary file 
1).
resource use
Costs included pharmacological therapies, hospitalisations, 
AEs and background medical management, including general 
practitioner visits and other outpatient contacts (see online 
Supplementary file 1). The costs of the ACEI (enalapril) and 
sacubitril/valsartan were based on the average doses taken in 
PARADIGM-HF (enalapril, 18.9 mg/day and sacubitril/valsartan, 
375 mg/day).10 Costs of background therapies were based on 
recommended doses and utilisation reported in PARADIGM-HF 
at baseline.10 The base year for costs was 2015.
The cost data used in the model are summarised in the online 
Supplementary file 1. The resource use for hospitalisations and 
AEs was assumed to be constant between model arms.
resuLts
statistical analysis
Full details of statistical models included in the economic model 
are provided in the online Supplementary file 1.
The model of CV mortality estimated a HR for sacubitril/
valsartan of 0.81 (P<0.001), which was consistent with the 
primary statistical analysis in PARADIGM-HF.10 Baseline EQ-5D 
was a highly significant predictor of CV mortality (P<0.001).
Similarly, the model of all-cause hospitalisation estimated a 
rate ratio for sacubitril/valsartan of 0.84 (P<0.001). Baseline 
EQ-5D was again observed to be a highly significant predictor 
(P<0.001). The predicted average annual rates of all-cause hospi-
talisation were 0.42 and 0.50 for sacubitril/valsartan and enal-
april, respectively, congruent with the results of PARADIGM-HF.
The results varied slightly between Denmark and the UK. This 
was due to the differing EQ-5D tariffs applied, as baseline EQ-5D 
was included as an independent variable in all models. However, 
the treatment effects for sacubitril/valsartan were almost iden-
tical in all three countries (see the online Supplementary file 1).
In the UK, the model predicted a mean life expectancy of 
9.27 and 8.36 years for sacubitril/valsartan and ACEI, respec-
tively, indicating an additional 0.91 years of life with sacubitril/
valsartan treatment. All-cause mortality at year 5 was estimated 
to be 33% and 38% for sacubitril/valsartan and ACEI, respec-
tively (table 3).
table 2 Summary of differences between models
component uK denmark colombia
Population PARADIGM-HF Reweighted 
PARADIGM-HF
PARADIGM-HF
Analysis type Patient-level 
analysis
Patient-level 
analysis
Patient-level 
analysis
Mortality CV mortality from 
PARADIGM-HF+life 
tables
CV mortality from 
PARADIGM-HF+life 
tables
CV mortality from 
PARADIGM-HF+life 
tables
EQ-5D tariff Dolan Wittrup-Jensen Dolan
Discontinuation 
considered in the 
base case?
No No No
CV, cardiovascular; PARADIGM-HF, Prospective comparison of ARNI with ACEI to 
Determine Impact on Global Mortality and morbidity in Heart Failure.
table 3 Model predicted clinical outcomes over lifetime unless otherwise stated
component
AceI sacubitril/valsartan Incremental
uK denmark colombia uK denmark colombia uK denmark colombia
Life expectancy, years 8.36 7.34 7.95 9.27 8.07 8.78 0.91 0.73 0.83
Number of HF hospitalisations per patient 0.89 0.82 0.85 0.84 0.76 0.79 −0.05 −0.05 −0.05
Number of CV hospitalisations per patient 2.18 2.01 2.08 2.06 1.88 1.95 −0.13 −0.13 −0.13
All-cause hospitalisations 3.50 3.22 3.34 3.30 3.01 3.13 −0.20 −0.21 −0.21
All-cause mortality (%) at year 2 16% 20% 17% 14% 17% 15% −0.02 −0.02 −0.02
All-cause mortality (%) at year 5 38% 44% 40% 33% 40% 36% −0.05 −0.04 −0.04
All-cause mortality (%) at year 10 66% 72% 68% 60% 67% 63% −0.05 −0.04 −0.05
ACEI, angiotensin-converting-enzyme inhibitor; CV, cardiovascular; HF, heart failure.
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In Denmark, the predicted mean life expectancy was 7.34 for 
the ACEI arm and 8.07 for the sacubitril/valsartan arm, a gain 
of 0.73 years of life. All-cause mortality at year 5 was estimated 
to be 40% and 44% in the sacubitril/valsartan and ACEI arms, 
respectively (table 3).
In Colombia, predicted mean life expectancy in the ACEI arm 
was 7.95 years and in the sacubitril/valsartan arm was 8.78, a 
gain of 0.83 years. All-cause mortality at year 5 was estimated 
to be 36% and 40% in the sacubitril/valsartan and ACEI arms, 
respectively (table 3).
A longitudinal analysis estimated that the EQ-5D scores 
declined at a rate of 0.008 per year across both arms when using 
the Dolan tariff and 0.006 per year when using the Wittrup-
Jensen tariff. Sacubitril/valsartan was associated with a small but 
statistically significant positive effect on EQ-5D, compared with 
enalapril, after adjusting for baseline characteristics (including 
baseline EQ-5D), hospitalisation, AEs and time. The absolute 
mean difference in EQ-5D score between treatments, after 
randomisation, was 0.011 (P<0.001) using the Dolan tariff and 
0.009 (P<0.001) using the Wittrup-Jensen tariff. Hospitalisation 
for any reason within the previous 30 days was associated with a 
reduction in EQ-5D of 0.105 (P<0.001), compared with those 
who were not hospitalised, and hospitalisation 30–90 days previ-
ously was associated with a reduction of 0.054 (P<0.001).
cost-effectiveness and model outcomes
UK setting
Sacubitril/valsartan treatment led to an additional (discounted) 
lifetime cost of £8906 per patient. Incremental acquisition costs 
of sacubitril/valsartan (£8665 per patient) were partly offset by 
savings attributable to reduced hospitalisation costs (£598 per 
patient). Sacubitril/valsartan treatment was associated with a 
QALY gain of 0.52, with a cost per QALY gained of £17 100 
(€20 393) (table 4).
Danish setting
Treatment with sacubitril/valsartan led to a lifetime incremental 
cost of Kr80 984 and an incremental QALY gain of 0.47, 
resulting in an ICER of Kr174 000 (€22 620, table 4).i The incre-
mental acquisition costs of sacubitril/valsartan (Kr88 540 per 
i Results presented here use the reweighted population to remain in line 
with Danish HTA submissions. Costs and QALYs increase in both arms 
when using an unweighted population; however, the ICER remains 
similar at Kr170 000.
patient) were partially offset by a reduction in hospitalisation 
costs (Kr10 102 per patient).
Colombian setting
Sacubitril/valsartan was associated with an incremental lifetime 
cost of COP$16 723 507 and an incremental QALY gain of 0.42, 
giving an ICER of COP$39.5 million (€15 975) per QALY gained 
(table 4). The incremental acquisition costs of sacubitril/valsartan 
(COP$17 424 660 per patient) were partially offset by a reduction 
in hospitalisation costs (COP$1 406 331 per patient).
Estimates of cost-effectiveness were consistent across 
subgroups (detail provided in the online Supplementary file 1).
deterministic sensitivity analysis
In all the three settings, the three most influential parameters 
were the coefficient for sacubitril/valsartan, the age-squared 
coefficient and the constant coefficient in the Gompertz model 
of CV mortality (figure 2).
In the UK setting, the most influential variable was the 
constant coefficient, which increased the ICER to £26 500 
at the upper limit of the 95% CI and decreased it to £12 700 
at the lower limit. The coefficient for sacubitril/valsartan, the 
age-squared coefficient and the constant coefficient in the 
Gompertz model of CV mortality were the only parameters to 
produce an ICER over £20 000 (figure 2).
In the Danish setting, the coefficient for sacubitril/valsartan, the 
age-squared coefficient and the constant coefficient in the Gompertz 
model of CV mortality were the only three parameters to generate 
an ICER over Kr250 000. The most influential parameter was the 
age-squared term in the regression model for CV mortality, which 
increased the ICER to Kr285 700 at the upper limit and reduced it 
to Kr116 100 at the lower limit (figure 2).
In the Colombian setting, the constant coefficient for CV 
mortality was the most influential parameter, which produced 
an ICER of COP$24.1 million at the lower limit of the 95% CI 
and an ICER of COP$55.0 million at the upper limit. No param-
eter produced an ICER above the willingness-to-pay (WTP) 
threshold of COP$52.4 million (figure 2).
Probabilistic sensitivity analysis (PsA)
In the UK, the expected ICER from the PSA was £18 000 (95% CI 
£8900 to £34 700). At cost-effectiveness thresholds of £20 000 and 
£30 000 per QALY gained, the probabilities that sacubitril/valsartan 
was cost-effective were 68% and 94%, respectively (figure 3).
table 4 Base case cost-effectiveness results (per patient) estimated over lifetime
component
AceI sacubitril/valsartan Incremental
uK (GbP)
denmark 
(dKK)
colombia 
(cOP) uK (GbP)
denmark 
(dKK)
colombia 
(cOP) uK (GbP)
denmark 
(dKK)
colombia 
(cOP)
Primary therapy costs 170 1281 3 575 530 8836 89 821 21 000 189 8665 88 540 17 424 660
Background therapy costs 607 5729 4 138 229 662 6226 4 478 344 55 497 340 116
Hospitalisation costs 8296 132 368 17 679 700 7697 122 267 16 273 369 −598 −10 102 −1 406 331
HF management costs 5639 5605 3 792 947 6153 6091 4 104 685 514 486 311 737
Adverse events 102 364 98 318 110 393 100 044 8 29 1725
Titration 0 0 0 262 1534 51 600 262 1534 51 600
Total costs 14 814 145 346 29 284 724 23 720 226 330 46 008 231 8906 80 984 16 723 507
QALYs 5.06 4.81 4.52 5.58 5.27 4.95 0.52 0.47 0.42
ICER 17 134 173 994 39 522 754
ACEI, angiotensin-converting-enzyme inhibitor; COP, Colombian peso; DKK, Danish kroner; GBP, British pound sterling; HF, heart failure; ICER, incremental cost-effectiveness ratio; 
QALY, quality-adjusted life-years.
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In Denmark, the expected ICER from PSA was Kr176 700 
(95% CI Kr76 200 to Kr367 300). The probability that sacubi-
tril/valsartan was cost-effective at Kr250 000 was 84% (figure 3).
In Colombia, the expected ICER from the PSA was 
COP$33.8 million. The probability of being cost-effective at a 
WTP threshold of COP$52.4 million (three times the average 
per capita income) was 95% (figure 3).
dIscussIOn
The base-case analysis for the UK indicates that sacubitril/
valsartan was cost-effective at a WTP threshold of £20 000 per 
QALY, compared with an ACEI, with an ICER of £17 100. This 
result was not only mainly driven by reductions in mortality but 
also by improvements in HRQL and reductions in hospitalisa-
tion. The findings of the analysis were robust to changes in most 
structural assumptions, and a PSA suggested that the probability 
that sacubitril/valsartan was cost-effective at a WTP threshold 
of £20 000 was 68%. Three analyses from the perspective of 
third-party healthcare payers in the USA have also suggested that 
sacubitril/valsartan is cost-effective at commonly accepted WTP 
thresholds.21–23
Our findings were consistent across all three countries. The 
base-case analysis for Denmark, another high-income country, 
found that sacubitril/valsartan was cost-effective at a WTP 
Figure 2 Tornado diagrams. ICER, incremental cost-effectiveness ratio.
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threshold of Kr250 000 per QALY, compared with an ACEI, with 
an ICER of Kr174 000. The base-case analysis for Colombia, 
a middle-income country, found that sacubitril/valsartan was 
cost-effective at a WTP threshold of COP$52.4 million per 
QALY, with an ICER of COP$39.5 million.
These results are in line with National Institute for Health and 
Care Excellence (NICE) guidance, which recommends sacubitril/
valsartan as a cost-effective option for the treatment of HF-REF 
in patients with NYHA class II–IV, a left ventricular ejection frac-
tion of ≤35% and who are already taking a stable dose of ACEI or 
ARB.24
The UK analysis predicted (discounted) gains in life years and 
QALYs with sacubitril/valsartan of 0.62 (9%) and 0.52 (10%), 
respectively. These are comparatively large benefits in terms of 
absolute and relative gains compared with the benefits of other 
treatments for HF-REF, especially as PARADIGM-HF was an 
active-controlled rather than placebo-controlled trial. The 
statistical models of mortality presented here were developed to 
align with the methods outlined by the NICE Decision Support 
Unit.25 This approach provides shorter estimates of survival 
in both arms of the model than have been estimated using 
non-parametric methods from PARADIGM-HF and correspond-
ingly lower gains in life expectancy.26 Given the importance of 
mortality as a determinant of cost-effectiveness in the present 
analysis, such estimates may provide a conservative estimate of 
cost-effectiveness for sacubitril/valsartan.
The observation that cost-effectiveness in this analysis was mainly 
driven by improvements in mortality is consistent with the results 
of some, but not all, prior analyses.27 However, other model-based 
studies concluded that reductions in hospitalisation are the key 
determinant of cost-effectiveness.28 This difference may be a conse-
quence of the different analytical approaches. This model consid-
ered independent statistical models of mortality, hospitalisation 
and long-term HRQL changes, and the relationships between these 
outcomes were contained implicitly in the analysis. In contrast, the 
model of Lee et al28 considered mortality and long-term HRQL to 
be direct functions of the number of hospitalisations experienced 
by an individual, and therefore model outcomes were conditional 
on the rate of hospitalisation itself. Nevertheless, both this model 
and that of Lee et al predicted that the proportions of QALY gains 
attributable to life extension were of similar magnitude for their 
respective interventions (88% and 80% in this model and in Lee et 
al, respectively). The cost savings attributable to reduced hospital-
isation were also of a similar magnitude (8% and 12% in this model 
and in Lee et al, respectively). These differences in the conclusions 
therefore appear to reflect decisions made in the conceptual design 
of the respective analyses.
The present evaluation used methods consistent with a 
recently published economic evaluation in HF,27 but incorpo-
rated a novel approach to the prediction of HRQL, in which 
EQ-5D was extrapolated based on time trends observed in 
PARADIGM-HF. A key strength of this analysis was that PARA-
DIGM-HF collected EQ-5D at multiple time points, permitting 
this longitudinal analysis. This allowed the direct modelling of 
EQ-5D over time, rather than predicting HRQL based on inter-
mediate clinical measures such as NYHA class.
The key limitation of this analysis was the extrapolation beyond 
the follow-up of PARADIGM-HF (with median follow-up of 
27 months). This is a cause of uncertainty which cannot readily 
be characterised in sensitivity analysis, but is common to all 
modelling exercises, particularly in HRQL estimates. However, 
the assumption of an annual decline in EQ-5D of 0.008 appears 
consistent with data from other studies; 1-year longitudinal data 
presented by Berg et al in patients with chronic HF suggests an 
annual decrease in EQ-5D of 0.006.29
PARADIGM-HF was a geographically diverse study, and the 
patient population may not be generalisable to individual countries. 
Although there is no evidence that the treatment effect differed 
across subgroups in PARADIGM-HF,10 cost-effectiveness is driven 
by absolute benefit, which is dependent on patients’ absolute risk 
of events, reflecting their baseline clinical characteristics. If patient 
characteristics differ between PARADIGM-HF and the HF-REF 
population in the UK, Denmark or Colombia, then absolute benefit, 
and therefore cost-effectiveness, would be expected to differ too. 
However, the results of the subgroup and scenario analyses suggest 
that the conclusions of the base-case analysis would not change to 
any meaningful extent.
In conclusion, this analysis suggests that sacubitril/valsartan 
likely represents a cost-effective option in the treatment of 
HF-REF for the NHS in the UK, the Danish healthcare system 
and for the Colombian healthcare system.
Figure 3 Cost-effectiveness acceptability curves.
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Key messages
What is already known on this subject?
Prospective comparison of ARNI with ACEI to Determine Impact 
on Global Mortality and morbidity in  Heart Failure trial showed 
that sacubitril/valsartan, an angiotensin receptor neprilysin 
inhibitor, was superior to the ACE inhibitor enalapril in reducing 
the risks of death and heart failure hospitalisation in patients 
with heart failure with reduced ejection fraction. Published 
analyses from the perspective of third-party healthcare payers in 
the USA have suggested that sacubitril/valsartan is cost-effective 
at commonly accepted willingness-to-pay thresholds.
What might this study add?
We evaluated the cost-effectiveness of sacubitril/valsartan 
compared with enalapril in the treatment of heart failure 
with reduced ejection fraction from the perspectives of the 
UK National Health Service, the Danish healthcare system 
(high-income countries) and the Colombian healthcare system 
(middle-income country). We found sacubitril/valsartan to be 
cost-effective at conventional willingness-to-pay thresholds in all 
three country settings.
how might this impact on clinical practice?
This analysis, which shows sacubitril/valsartan to be a cost-
effective use of resources, should aid decision-makers and may 
enhance availability of this efficacious treatment for patients 
with heart failure with reduced ejection fraction.
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